In June 2025, the U.S. Food and Drug Administration (FDA) approved Yeztugo (lenacapavir), which is the first and only twice-yearly injection for HIV prevention. This means that people at risk for HIV can now get long-acting protection with just two injections per year. NeedyMeds understands that new medicines often comes with high price tags. That’s why we keep track of any manufacturer savings program we can find, and allow them to be easily searchable on our website. Thankfully, Gilead, the manufacturer of Yeztugo, offers programs that can significantly reduce or even eliminate the cost. In this blog, we’ll talk about […]